Request Trial
24 July 2026NewsIn-house counselSarah Speight

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

As Philips' Kevin Scott becomes the IP Federation’s new president, Sarah Speight discovers the key issues facing the membership body for in-house counsel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

In-house counsel
CIPA Congress: Sustainability is essential for the profession and the planet
18 September 2026   At an event attended by patent experts and judges from Europe, the US and China, delegates gathered in the innovation hub of Manchester, UK, to debate the theme of sustainability "in its broadest sense". Sarah Speight was there to hear ideas spanning the commercialisation of clean tech, to ensuring the patent profession’s resilience in a time of colossal change.
In-house counsel
Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice
4 August 2026   A transatlantic firm with intellectual property at its heart—what’s not to like? The firm’s 30-year veteran tells WIPR why leading a recruitment drive is a “big responsibility” as the combined firm looks to out-scale the opposition.
In-house counsel
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
13 July 2026   The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Behind the case: How Novartis defended its blockbuster Entresto in the UK
Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight
Benesch adds former McDermott IP practice head
Leading European patent litigator to join Carpmaels & Ransford
CIPA Congress: Sustainability is essential for the profession and the planet
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Amgen hit with lawsuit over its proposed Opdivo biosimilar